Showing results (51-60 of 182) with videos related to
Sort By:
Pageof 19
Gastroenterology|January 15, 2023
AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewBruce Wang, Herbert L Bonkovsky, Joseph K Lim, et al.Journal of Clinical Gastroenterology|November 4, 2017
Management of Chronic Hepatitis C in End-stage Renal DiseaseVeronica Angulo-Diaz, Joseph K Lim, Paul Martin, et al.Gastroenterology|October 20, 2020
AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert ReviewMichael Dougan, Yinghong Wang, Alberto Rubio-Tapia, et al.World Journal of Virology|June 27, 2025
Advances in treatment of hepatitis delta virus infection: Update on novel investigational drugsJiyoon Park, Amr Sayed, Syed Alishan Nasir, et al.Liver International : Official Journal of the International Association for the Study of the Liver|September 26, 2022
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbookAriel Jaffe, Tamar H Taddei, Edoardo G Giannini, et al.Journal of Clinical Gastroenterology|July 11, 2006
The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of lifeJoseph K Lim, Ruth Cronkite, Mary K Goldstein, et al.Gastroenterology|February 2, 2020
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert ReviewRohit Loomba, Joseph K Lim, Heather Patton, et al.Journal of Clinical and Translational Hepatology|December 9, 2024
Advanced Liver Fibrosis Predicts Liver Outcomes in Biopsy-proven Metabolic Dysfunction-associated Steatotic Liver Disease: A U.S.-based Single-center Retrospective Cohort StudyRobert Lam, Dhanpat Jain, Yanhong Deng, et al.Gastroenterology|October 21, 2018
Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining ChallengesThomas F Baumert, Thomas Berg, Joseph K Lim, et al.European Journal of Gastroenterology & Hepatology|May 21, 2020
Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health systemYsabel C Ilagan-Ying, Jin Xu, Joseph K Lim, et al.Pageof 19